Clinical trials: Anger
Anger, Stress
Hostile Bias Modification Training (HBMT) Study
The primary objective of the present protocol is to evaluate the effectiveness of real HBMT versus placebo on reducing HAB and aggression. The secondary objectives of the present protocol are: 1.
- Conditions
- Anger, Stress, Aggression
- Trial name
- NCT04997356
- Testing
- Hostile Bias Modification Training, Other training
- Where
- United States
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- Walter Reed Army Institute of Research (WRAIR)
Presumptive NAFLD
A Study of EDP 305 in Healthy Subjects and Subjects With Presumptive NAFLD
This randomized, double-blind, placebo-controlled study will assess the safety, tolerability, and pharmacokinetics of single and multiple orally administered doses of EDP-305 in healthy adult subjects, and adult subjects with…
- Trial name
- NCT02918929
- Testing
- EDP 305
- Where
- United States
- Volunteers
- 146 people, healthy volunteers welcome
- Sponsor
- Enanta Pharmaceuticals, Inc
Ebola Hemorrhagic Fever
A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7537 in Healthy Adult Volunteers
The purpose of this study is to evaluate the safety and tolerability of healthy male and female subjects with intravenous (IV) infusions of AVI 7537 compared to matched placebo in and to evaluate the pharmacokinetics (PK).
- Trial name
- NCT01593072
- Testing
- AVI-7537, Normal Saline Solution (NSS)
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Sarepta Therapeutics, Inc.
Anger, Intermittent Explosive Disorder
Maladaptive Anger Treatment
From a psychoevolutionary perspective, anger is a universal emotion that can serve the function of making us aware of wrongdoing and motivating us to undo/correct the wrongdoing.
- Conditions
- Anger, Intermittent Explosive Disorder, Emotional Distress, Aggression
- Trial name
- NCT06275607
- Testing
- Cognitive Behavioral Affective Therapy, Emotional Discussion
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- The University of Texas at San Antonio
Safety, Tolerability
A First-in-Human SAD and MAD Study in HV to Evaluate Oral YR011 Tablet
This is a Phase I clinical trial (protocol number: YR-011-B07) sponsored by Hangzhou Yirui Pharmaceutical Technology Co., Ltd., focusing on the novel oral small-molecule drug YR011 (active ingredient: PA032, a Kv1.3 channel…
- Conditions
- Safety, Tolerability, Pharmacokinetic
- Trial name
- NCT07878481
- Testing
- Kv1.3 potassium channel blocker (PA032, investigational oral small-molecule drug)
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Hangzhou Yirui Pharmaceutical Technology Co., Ltd
Healthy Volunteers
Multiple Ascending Doses (MAD) of AZD3199 Given Once Daily as Inhaled Formulation Via Turbuhaler to Healthy Men
The purpose of this study is to investigate the safety and tolerability of multiple once daily ascending doses of AZD3199 in healthy men
- Trial name
- AZD3199MAD (NCT00713271)
- Testing
- AZD3199
- Where
- Sweden
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Anger Problems, Aggression
Treatment of Chronic Anger and Aggression Following Military-Related Betrayal
The goal of this clinical trial is to learn if a treatment designed to deal with anger and aggression from a past betrayal will work. The study will be done on active duty military service members and veterans aged 18 or older.
- Trial name
- CART (NCT06609330)
- Testing
- Countering Chronic Anger and Aggression Related to Trauma and Transgressions (CART)
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Safety Issues
Safety, Tolerability, and Pharmacokinetics of EQU-001 in Healthy Volunteers
This is a randomized, placebo-controlled, double-blinded single and multiple ascending dose (SAD and MAD) study of the safety, tolerability, and pharmacokinetics of EQU-001 in healthy volunteers.
- Trial name
- NCT05004571
- Testing
- EQU-001
- Where
- United States
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Equilibre Biopharmaceuticals B.V.
Healthy Elderly
MAD Study of NX210c
This study will investigate the safety and tolerability of multiple intravenous infusions of NX210c with two ascending doses as well as NX210c pharmacokinetics (PK), and pharmacodynamics (PD) effects in healthy elderly subjects.
- Trial name
- CHDR2235 (NCT05827653)
- Testing
- NX210c
- Where
- Netherlands
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Axoltis Pharma
Cerebellum and Pain in Healthy Volunteers.
fMRI and DTI of Cerebellar Responses to Pain in the Human Trigeminal System
This K01 application is designed to prepare the applicant with the skills necessary to establish an independent research program on pain--related processing in the cerebellum.
- Trial name
- NCT01738126
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Mclean Hospital
Healthy
A Study to Investigate the Safety, Tolerability, Pharmacokinetics of ALZ002 DS in Healthy Volunteers
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of single-ascending and multiple-ascending doses of ALZ002 DS.
- Trial name
- NCT04392830
- Testing
- ALZ002 DS
- Where
- Australia
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- AnnJi Pharmaceutical Co., Ltd.
Healthy Volunteers
A SAD, MAD and Food Effect Study to Evaluate the Safety, Tolerability, PK, and PD of AJA001 in Healthy Subjects
This is a Phase 1, double-blind, randomized, placebo- controlled, SAD and MAD study to assess safety, tolerability, PK, and PD of AJA001 in fasted healthy participants.
- Trial name
- NCT06019065
- Testing
- AJA001
- Where
- Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- AJNA Australia Pty Ltd
Complicated Urinary Tract Infections(cUTI)
Evaluation of the Safety, Tolerability and Pharmacokinetics of TUL108 for Injection in Healthy Participants (SAD/ MAD)
To evaluate the safety, tolerability and pharmacokinetics of single and multiple intravenous (IV) infusion of TUL108 in healthy participants.
- Trial name
- NCT07719257
- Testing
- TUL108
- Where
- China
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Zhuhai United Laboratories Co., Ltd.
Healthy Postmenopausal Women
Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KSHN001034 in Healthy Postmenopausal Female Volunteers
The goal of this clinical trial is to evaluate if KSHN001034 demonstrates safety, tolerability, and a comparable pharmacokinetic (PK) profile to the reference product, Faslodex® (fulvestrant), which is used for the treatment of…
- Trial name
- NCT06995482
- Testing
- KSHN001034, Fulvestrant
- Where
- 2 sites in United States, India
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Kashiv BioSciences, LLC
Healthy
A First in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled ETD002 in Healthy Subjects
This is a first in human study of ETD002 a new drug being developed for the treatment of cystic fibrosis.The study is a randomised, double-blind, placebo-controlled, interventional study to assess the safety and tolerability of…
- Trial name
- NCT04488705
- Testing
- ETD002 - single dose, ETD002 - 7 day repeat dose, ETD002 - 14 day repeat dose
- Where
- United Kingdom
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Enterprise Therapeutics Ltd
Part I (SAD) - Healthy Participants, Part II (MAD) - Chronic Obstructive Pulmonary Disease
Safety and Tolerability of MEDI3506 in Healthy Participants, in Participants With COPD and Healthy Japanese Participants
This is a Phase 1, randomised, blinded, placebo controlled, study designed to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity response to single and multiple doses of MEDI3506.
- Conditions
- Part I (SAD) - Healthy Participants, Part II (MAD) - Chronic Obstructive Pulmonary Disease, Part III (J-SD) - Healthy Japanese Participants
- Trial name
- NCT03096795
- Testing
- MEDI3506
- Where
- 2 sites in United Kingdom
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Anxiety Disorder, PTSD
Peer-led Group Intervention for Coping With Disaster
The present project partners with leading faith communities in Houston to provide expert-led educational workshops to a diverse sample of adults on normative and concerning response to disaster.
- Conditions
- Anxiety Disorder, PTSD, Depressive Symptoms, Anger
- Trial name
- NCT03907995
- Testing
- Cognitive Behavioral Therapy
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Baylor College of Medicine
Healthy, Rheumatoid Arthritis
MAD Study of IA-14069
The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple ascending oral doses of IA-14069 in healthy subjects and in patients with RA on stable dosese of MTX, with…
- Trial name
- NCT05533372
- Testing
- IA-14069, Methotrexate
- Where
- United States
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- ILAb Co., Ltd.
Parenting, Anxiety
Parental Stress After the Covid-19 Pandemic
The aim of this study is to investigate the levels of parental stress 3 months after (T2) the strict physical distancing government initiated physical distancing protocols related to the COVID-19 pandemic (T1).
- Conditions
- Parenting, Anxiety, Depression, Anger
- Trial name
- NCT04442308
- Volunteers
- 1,440 people, healthy volunteers welcome
- Sponsor
- University of Oslo
Amyotrophic Lateral Sclerosis
Dexpramipexole SAD/MAD Study
This Phase 1 study will explore the safety, tolerability, and pharmacokinetics of single doses ranging from 300 to 600 mg and multiple daily doses ranging from 225 mg to 300 mg BID dexpramipexole in healthy volunteers.
- Trial name
- NCT01449578
- Testing
- Dexpramipexole
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Knopp Biosciences